Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 1.00 |
| ▸ | SLC5A1 | P13866 | 13/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.70 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19494773 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL500488 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL14324871 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL24105577 | 0.92 | SLC5A2 (0.86) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL20124638 | 0.90 | SLC5A2 (0.81) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL499848 | 0.90 | SLC5A2 (0.81) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL499901 | 0.90 | SLC5A2 (0.81) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL27368116 | 0.88 | SLC5A2 (0.90) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL19494518 | 0.87 | SLC5A2 (0.79) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL14324857 | 0.87 | SLC5A2 (0.79) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3318562-A2 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | Theracos Sub, LLC (US) | 2018-05-09 | — | — | EP | claimed |
| EP-2187742-B1 | (2S,3R,4R,5S,6R)-2-(4-CHLORO-3-BENZYLPHENYL)-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL DERIVATIVES FOR USE IN THE TREATMENT OF DIABETES | THERACOS SUB LLC (US) | 2017-10-25 | — | — | EP | claimed |
| EP-2324002-B1 | PROCESSES FOR THE PREPARATION OF SGLT2 INHIBITORS | THERACOS SUB LLC (US) | 2016-10-05 | — | — | EP | claimed |
| US-8802637-B2 | Benzylbenzene derivatives and methods of use | THERACOS, INC. (US) | 2014-08-12 | — | — | US | claimed |
| US-20140031300-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2014-01-30 | — | — | US | claimed |
| JP-2012500803-A | — | — | 2012-01-12 | — | — | JP | claimed |
| JP-4809931-B2 | — | — | 2011-11-09 | — | — | JP | claimed |
| EP-2324002-A2 | PROCESSES FOR THE PREPARATION OF SGLT2 INHIBITORS | Theracos, Inc. (US) | 2011-05-25 | — | — | EP | claimed |
| US-7838499-B2 | Benzylbenzene derivatives and methods of use | THERACOS, INC. (US) | 2010-11-23 | — | — | US | claimed |
| US-20100222599-A1 | PROCESSES FOR THE PREPARATION OF SGLT2 INHIBITORS | THERACOSBIO, LLC | 2010-09-02 | — | — | US | claimed |
| EP-2187742-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | Theracos, Inc. (US) | 2010-05-26 | — | — | EP | claimed |
| WO-2010022313-A2 | PROCESSES FOR THE PREPARATION OF SGLT2 INHIBITORS | THERACOS, INC. (US) | 2010-02-25 | — | — | WO | claimed |
| US-20090118201-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOSBIO, LLC | 2009-05-07 | — | — | US | claimed |
| WO-2009026537-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2009-02-26 | — | — | WO | claimed |
| EP-3318562-A2 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | Theracos Sub, LLC (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-2187742-B1 | (2S,3R,4R,5S,6R)-2-(4-CHLORO-3-BENZYLPHENYL)-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL DERIVATIVES FOR USE IN THE TREATMENT OF DIABETES | THERACOS SUB LLC (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-2187742-B1 | (2S,3R,4R,5S,6R)-2-(4-CHLORO-3-BENZYLPHENYL)-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL DERIVATIVES FOR USE IN THE TREATMENT OF DIABETES | THERACOS SUB LLC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20090118201-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOSBIO, LLC | 2009-05-07 | — | — | US | disclosed |
| WO-2009026537-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009026537-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118201-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | SLC5A2, SLC5A1, SLC2A4 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 1525/4885 |
| US-20100222599-A1 | PROCESSES FOR THE PREPARATION OF SGLT2 INHIBITORS | SLC5A2, SLC5A1, SLC2A4 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 1802/4885 |
| US-20140031300-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | SLC5A2, SLC5A1, SLC2A4 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.